• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Under threat: mRNA vaccine research
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld MedTech

BioWorld MedTech

April 1, 2021

View Archived Issues
pancreas-insulin-diabetic.png

Bluestar Genomics gets breakthrough nod for pancreatic cancer screening test

Pancreatic cancer is the third leading cause of cancer death in the U.S., in part because many cases aren’t diagnosed until they are advanced. Bluestar Genomics Inc. wants to change that with its epigenomics technology which can detect early pancreatic cancer from a standard blood draw by analyzing cell-free DNA in plasma. Now, the FDA has provided a bump, granting breakthrough device designation to Bluestar’s noninvasive pancreatic cancer detection test in patients with new-onset diabetes. According to the San Diego-based startup, of an estimated 60,000 patients diagnosed with pancreatic cancer in the U.S., nearly a fourth are found to have new-onset diabetes prior to receiving their cancer diagnosis. Read More
Jada device image

Merck spinoff Organon set to focus on women's health with $240M acquisition of Alydia

Merck & Co. Inc. telegraphed the future focus of Organon & Co., which will spin off from the pharmaceutical giant as a public company in the first half of 2021, with an announcement of an agreement to acquire Alydia Health Inc. Alydia makes the Jada system, which treats postpartum hemorrhage. Read More
Australia-flag-health-tech.png

Australian government funding boosts early-stage med-tech companies to enter clinical trials

PERTH, Australia – In a boost for Australia’s medical technology innovators, A$3.2 million (US$2.4 million) in partnership projects are being deployed to help get innovative new medical devices to the next steps of starting human trials and early-stage manufacturing. Read More
Man wears Neurovine device around forehead

Neurovine warns patients with concussion about overdoing their therapy

TORONTO – “There’s no magic pill that helps patients with concussion except physical activity,” Ashleigh Kennedy, CEO of Neurovine Inc. told BioWorld. But how does a patient in rehab know when to put on the brakes if they’re working too hard physically or mentally? Read More
coronavirus-COVID-19-globe.png

Global cases rise, but more weapons advance to combat COVID-19

As COVID-19 vaccinations continue to roll out, momentum builds with strong phase III data for what could become the fourth and fifth walls of defense in the U.S. Read More

Appointments and advancements for April 1, 2021

New hires and promotions in the med-tech industry, including: Clover Health, Eyenovia, Inscopix, Lantheus, Sciex, Second Sight, Spire Health. Read More

In the clinic for April 1, 2021

Clinical updates, including trial initiations, enrollment status and data readouts and publications: Uptake Medical. Read More

Other news to note for April 1, 2021

Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aditx Therapeutics, Collection Sites, Concert Genetics, Corvida Medical, Dalrada, Dedalus, Dx Medical Solutions, Dxc Technology, Egenesis, Euroimmun, Fresenius Kabi, Genematters, Guardant Health, Health Clinics, Invitae, Lifestance Health, Medivolve, Meridian Bioscience, Myomo, Ontrak, Pear Therapeutics, Perkinelmer, Premier, Prescryptive Health, Sqi Diagnostics, Stagezero Life Sciences. Read More

Regulatory actions for April 1, 2021

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abbott, Becton Dickinson, Bluestar Genomics, Inspire. Read More

Regulatory front for April 1, 2021

The latest global regulatory news, changes and updates affecting medical devices and technologies, including: MDIC accepting applications for the ASC pilot study. Read More

BioWorld MedTech’s Diagnostics Extra for April 1, 2021

Keeping you up to date on recent developments in diagnostics, including: Blood-based test may help detect early Alzheimer’s disease; AI-based tool helps predict course of COVID-19; Myeloid cells differ in primary and recurrent glioblastoma. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Sept. 18, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Sept. 18, 2025.
  • Dennis-Slamon speaks at GBC 25

    The ‘molecular revolution’ driving R&D of new cancer therapeutics

    BioWorld Asia
    “New explosions in biotechnology are allowing us to interrogate cancers at a very sophisticated level compared to before,” Dennis Slamon told audience members at...
  • Elderly woman holding illustration of brain with missing puzzle piece

    Remynd’s REM-127 yields positive phase II data in Alzheimer’s

    BioWorld
    Remynd NV has turned in positive phase IIa data for a new target in Alzheimer’s disease, showing that restoring calcium homeostasis in neurons reduces levels of...
  • Vial and syringe in row of dominoes

    The domino effect of cutting mRNA vaccine research

    BioWorld
    In August, a press release from HHS announced the cancellation of 22 vaccine research projects based on mRNA, the latest available technology aimed at developing...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe